Recordati Industria Chimica e Farmaceutica S.p.A.

LSE:0KBS Stock Report

Market Cap: €12.0b

Recordati Industria Chimica e Farmaceutica Valuation

Is 0KBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0KBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€70.31
Fair Value
16.7% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: 0KBS (€58.6) is trading below our estimate of fair value (€70.31)

Significantly Below Fair Value: 0KBS is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0KBS?

Key metric: As 0KBS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0KBS. This is calculated by dividing 0KBS's market cap by their current earnings.
What is 0KBS's PE Ratio?
PE Ratio28.3x
Earnings€423.12m
Market Cap€11.98b

Price to Earnings Ratio vs Peers

How does 0KBS's PE Ratio compare to its peers?

The above table shows the PE ratio for 0KBS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28x
HIK Hikma Pharmaceuticals
22.1x11.0%UK£5.1b
GSK GSK
22.9x18.4%UK£58.9b
AZN AstraZeneca
31.7x17.0%UK£179.9b
ANCR Animalcare Group
35.2xn/aUK£162.8m
0KBS Recordati Industria Chimica e Farmaceutica
28.3x11.1%€12.0b

Price-To-Earnings vs Peers: 0KBS is expensive based on its Price-To-Earnings Ratio (28.3x) compared to the peer average (28x).

Price to Earnings Ratio vs Industry

How does 0KBS's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0KBS 28.3xIndustry Avg. 22.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0KBS is expensive based on its Price-To-Earnings Ratio (28.3x) compared to the European Pharmaceuticals industry average (22.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0KBS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0KBS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.3x
Fair PE Ratio28.2x

Price-To-Earnings vs Fair Ratio: 0KBS is expensive based on its Price-To-Earnings Ratio (28.3x) compared to the estimated Fair Price-To-Earnings Ratio (28.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0KBS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€58.60
€56.64
-3.3%
11.2%€70.00€50.00n/a10
Feb ’26€58.75
€56.64
-3.6%
11.2%€70.00€50.00n/a10
Jan ’26€50.82
€55.74
+9.7%
9.6%€65.00€48.00n/a10
Dec ’25€51.55
€55.24
+7.2%
8.4%€63.00€48.00n/a10
Nov ’25€52.60
€55.04
+4.6%
8.2%€63.00€48.00n/a10
Oct ’25€50.95
€53.49
+5.0%
9.7%€62.00€45.00n/a10
Sep ’25€53.00
€53.49
+0.9%
9.7%€62.00€45.00n/a10
Aug ’25€50.80
€53.09
+4.5%
10.1%€62.00€45.00n/a10
Jul ’25€48.74
€52.64
+8.0%
10.8%€62.00€44.00n/a10
Jun ’25€48.40
€52.24
+7.9%
11.7%€62.00€44.00n/a10
May ’25€49.93
€52.14
+4.4%
12.0%€62.00€43.00n/a10
Apr ’25€51.23
€50.84
-0.8%
10.4%€57.00€43.00n/a10
Mar ’25€52.10
€50.04
-4.0%
12.1%€57.00€41.00n/a10
Feb ’25€50.95
€48.45
-4.9%
12.3%€57.00€41.00€58.7510
Jan ’25€48.73
€48.15
-1.2%
11.6%€56.00€41.00€50.8210
Dec ’24€44.19
€48.15
+9.0%
11.6%€56.00€41.00€51.5510
Nov ’24€43.92
€47.54
+8.2%
12.5%€56.00€41.00€52.6010
Oct ’24€45.01
€47.54
+5.6%
12.5%€56.00€41.00€50.9510
Sep ’24€45.72
€46.85
+2.5%
12.9%€56.00€40.00€53.0011
Aug ’24€46.62
€46.40
-0.5%
13.2%€56.00€38.00€50.8011
Jul ’24€43.76
€45.99
+5.1%
12.2%€54.00€38.00€48.7411
Jun ’24€42.53
€45.99
+8.1%
12.2%€54.00€38.00€48.4011
May ’24€41.38
€45.20
+9.2%
11.3%€52.00€37.00€49.939
Apr ’24€39.19
€44.98
+14.8%
10.8%€51.00€37.00€51.239
Mar ’24€39.15
€44.74
+14.3%
11.5%€51.00€35.00€52.1011
Feb ’24€39.21
€45.37
+15.7%
10.4%€53.00€39.00€50.9511
Analyst Price Target
Consensus Narrative from 10 Analysts
€56.64
Fair Value
3.5% overvalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 10:03
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paola SagliettiBanca Akros S.p.A. (ESN)
Charles Pitman-KingBarclays
Nicolas Guyon-GellinBNP Paribas Exane